Needham Maintains Buy on Surmodics, Raises Price Target to $47
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson maintains a Buy rating on Surmodics (NASDAQ:SRDX) and raises the price target from $44 to $47.
February 01, 2024 | 5:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Mike Matson maintains a Buy rating on Surmodics and raises the price target from $44 to $47.
The upgrade in price target by a reputable analyst like Mike Matson from Needham is a strong positive signal for Surmodics. It suggests confidence in the company's future performance and growth potential, likely leading to increased investor interest and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100